Gemigliptin Market Growth is Expected to be Flourished by Rising Geriatric Population Globally
![]() |
Gemigliptin Market |
Gemigliptin
is an oral antidiabetic drug belonging to the class of dipeptidyl peptidase-4
(DPP-4) inhibitors. Gemigliptin is used for the treatment of type 2 diabetes.
It is used as a monotherapy or in combination with other antidiabetic agents
such as metformin, sulphonylureas, or insulin. Gemigliptin helps control blood
sugar levels by enhancing the effect of substances in the body that work to
lower blood sugar. It works by inhibiting the enzyme DPP-4, which breaks down
incretin hormones like GLP-1. Increasing the levels of these hormones helps the
pancreas produce and release more insulin when blood sugar levels rise.
The
global gemigliptin market is estimated to be valued at US$ 1.79 Bn in 2023 and
is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
The global gemigliptin market is driven by rising geriatric population
worldwide coupled with growing prevalence of diabetes globally. According to
data by the American Diabetes Association, more than 37 million people in the
United States had diabetes in 2019. Further, the number of people diagnosed is
expected to keep on increasing considerably over the forecast period, supported
by growing diabetes burden around the world. This will boost adoption of
antidiabetic drugs like gemigliptin.
Market Dynamics:
One key driver for the gemigliptin market referred from the heading is rising
geriatric population globally. Elderly people are more prone to develop
diabetes due to age-related deterioration of pancreatic beta-cell function.
According to UN data, the number of people aged 65 years or older is projected
to grow from 703 million in 2019 to 1.5 billion in 2050 globally. This raises
the risk of diabetes significantly. Therefore, growing geriatric demography
presents huge opportunities for manufacturers of antidiabetic drugs such as
gemigliptin. Additionally, increasing prevalence of diabetes is another key
factor fueling demand for antidiabetic therapies like gemigliptin. According to
International Diabetes Federation, approximately 537 million adults were living
with diabetes in 2021 worldwide and the number is expected to rise to 643
million by 2030 and 783 million by 2045. Rising diabetes incidence ramps up the
need for effective antidiabetic treatment regimens including DPP-4 inhibitor
drugs like gemigliptin.
Segment Analysis
The global gemigliptin market is dominated by the hospital pharmacy sub-segment
which holds around 55% of the market share. This is because majority of the
patients are given gemigliptin prescription by their doctors during their
hospital visit or stay. However, the online pharmacy sub-segment is witnessing
highest growth and is expected to be the fastest growing sub-segment during the
forecast period. Increased adoption of e-commerce and rise of telehealth and
telemedicine are some key factors supporting the growth of online pharmacy
sub-segment.
PEST Analysis
Political: The regulations around marketing and sales of new drugs are
stringent which impacts the entry of new players in the market. However,
governments support and funds research & development activities for novel
drugs to treat chronic diseases.
Economic: Rising healthcare expenditure and increasing disposable income is
positively impacting the growth of the market. Higher margins and less
competition for novel drugs also attracts investments from big pharmaceutical
companies.
Social: Growing geriatric population prone to diabetes and obesity is the major
factor driving the social need. Increased awareness about management of chronic
diseases also supports growth.
Technological: Advancements in drug delivery methods and addition of
complementary technologies like AI, IoT supports remote monitoring. Emerging
economies are witnessing improved connectivity essential for telehealth and
online pharmacies.
Key Takeaways
The Global
Gemigliptin Market Share size was valued at US$ 1.79 Bn in 2024 and is
expected to reach US$ 2.46 Bn by 2030, expanding at a CAGR of 6.0% during the
forecast period.
Regional analysis
The gemigliptin market in Asia Pacific region currently dominates with around
45% market share majorly led by China, India and Japan. This is due to growing
diabetic population, favourable regulations and presence of local
pharmaceutical giants. North America and Europe are other major markets and
together hold over 40% share due to rising healthcare costs and growing elderly
population.
Key players
Key players operating in the gemigliptin market are Samsung, Apple Inc.,
Microsoft Corporation, Mozo Accessories, iLuv Creative Technology, Energizer,
Case-mate, and Muvit. Samsung capturing around 20-25% market share due to wider
product portfolio and geographic presence. Apple Inc. is second largest player
focusing on developed markets while local Chinese manufacturers like Mozo are
gaining grounds in Asia.
For more details on the report, Read- https://www.ukwebwire.com/gemigliptin-market-demand-share-analysis/
Comments
Post a Comment